Author

Leanne Ianniello

Institution: Beam Therapeutics (United States)

Observed institution: Beam Therapeutics (United States)

OpenAlex ID: A5115023085

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

2024 · Ashish O. Gupta, Akshay Sharma, et al. · Blood · 17

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

2025 · Ashish Gupta, Akshay Sharma, et al. · Blood · 2

Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study

2025 · Ashish O. Gupta, Akshay Sharma, et al. · Transplantation and Cellular Therapy

Works count: 3

Citation count: 19

H-index: 2

I10-index: 1